(Q33430055)

English

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Katherine K Matthay

18

object named as

Katherine K Matthay

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

object named as

John M Maris

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Steven G DuBois

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Araz Marachelian

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Elizabeth Fox

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rachel A Kudgus

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joel M Reid

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Susan Groshen

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jemily Malvar

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rochelle Bagatell

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lars Wagner

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Randall Hawkins

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jesse Courtier

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hollie Lai

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fariba Goodarzian

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hiroyuki Shimada

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scarlett Czarnecki

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Denice Tsao-Wei

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yael P Mosse

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

16 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1368-1375

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Drugging MYCN through an allosteric transition in Aurora kinase A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Reducing irinotecan-associated diarrhea in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

21 June 2018

Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

31 October 2018

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

31 October 2018

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

31 October 2018

Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872349

31 October 2018

A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26884555

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese

1 reference

https://pubmed.ncbi.nlm.nih.gov/26884555

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Camptothecins: a review of their development and schedules of administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/26884555

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/26884555

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Shortening the timeline of pediatric phase I trials: the rolling six design

1 reference

https://pubmed.ncbi.nlm.nih.gov/26884555

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2015.65.4889

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33430055&oldid=2186461653"